- Home
- CAPR vs NEXN Comparison
CAPR vs NEXN Comparison
Compare CAPR & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- NEXN
- Stock Information
- Founded
- CAPR 2005
- NEXN 2007
- Country
- CAPR United States
- NEXN Israel
- Employees
- CAPR N/A
- NEXN N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- NEXN Computer Software: Programming Data Processing
- Sector
- CAPR Health Care
- NEXN Technology
- Exchange
- CAPR Nasdaq
- NEXN Nasdaq
- Market Cap
- CAPR 578.4M
- NEXN 645.6M
- IPO Year
- CAPR N/A
- NEXN 2021
- Fundamental
- Price
- CAPR $14.06
- NEXN $9.88
- Analyst Decision
- CAPR Strong Buy
- NEXN Strong Buy
- Analyst Count
- CAPR 7
- NEXN 5
- Target Price
- CAPR $39.29
- NEXN $10.20
- AVG Volume (30 Days)
- CAPR 1.1M
- NEXN 127.3K
- Earning Date
- CAPR 02-27-2025
- NEXN 03-05-2025
- Dividend Yield
- CAPR N/A
- NEXN N/A
- EPS Growth
- CAPR N/A
- NEXN N/A
- EPS
- CAPR N/A
- NEXN 0.09
- Revenue
- CAPR $23,228,045.00
- NEXN $349,109,000.00
- Revenue This Year
- CAPR N/A
- NEXN $7.66
- Revenue Next Year
- CAPR $74.85
- NEXN $7.80
- P/E Ratio
- CAPR N/A
- NEXN $47.12
- Revenue Growth
- CAPR 65.33
- NEXN 1.55
- 52 Week Low
- CAPR $3.52
- NEXN $4.61
- 52 Week High
- CAPR $23.40
- NEXN $10.94
- Technical
- Relative Strength Index (RSI)
- CAPR 48.54
- NEXN 49.20
- Support Level
- CAPR $12.31
- NEXN $9.84
- Resistance Level
- CAPR $16.17
- NEXN $10.26
- Average True Range (ATR)
- CAPR 0.82
- NEXN 0.33
- MACD
- CAPR 0.11
- NEXN -0.06
- Stochastic Oscillator
- CAPR 45.34
- NEXN 28.38
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.